



PUBLICATIONS 2011 - AUTRES COMMUNICATIONS

Autres

6. **Denys P**, Chartier-Kastler E. Reply from Authors re: Christopher R. Chapple. Finding the Correct Starting Dose for OnabotulinumtoxinA. Eur Urol. In press. DOI:10.1016/j.eururo.2011.12.008. Eur Urol. 2011 Dec. IF 8.843
7. Oger S, Behr-Roussel D, Gorny D, Bernabé J, Comperat E, Chartier-Kastler E, **Denys P**, Giuliano F. Effects of potassium channel modulators on myogenic spontaneous phasic contractile activity in human detrusor from neurogenic patients. BJU Int. 2011 Aug;108(4):604-11. IF 3.190
8. **Orlikowski D, Pellegrini N, Prigent H**, Laforêt P, Carlier R, Carlier P, Eymard B, **Lofaso F, Annane D**. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuromuscul Disord. 2011 Jul;21(7):477-82. IF 2.764
9. **Pradon D**, Hutin E, Khadir S, Taiar R, **Genet F, Roche N**. A pilot study to investigate the combined use of Botulinum toxin type-a and ankle foot orthosis for the treatment of spastic foot in chronic hemiplegic patients. Clin Biomech (Bristol, Avon). 2011 Oct; 26(8):867-72. IF 2.036
10. Schnitzler A, **Genet F, Durand MC, Roche N, Bensmail D**, Chartier-Kastler E, **Denys P**. Pilot study evaluating the safety of intradetrusor injections of botulinum toxin type A: Investigation of generalized spread using single-fiber EMG. Neurourol Urodyn. 2011 Nov;30(8):1533-7. IF 2.903
11. **Denys P**, Lenormand L, Ghout I, Costa P, Chartier Kasler E, Grise P, Hermieu J, Amarenco G, Karsenty G, Saussine C, **Barbot F** for the Vesitox study group in

- France. Efficacy and safety of low doses of onabotulinumtoxin A for the treatment of refractory idiopathic overactive bladder: a multicenter, double-blind, randomised, placebo controlled dose-ranging study. *Eur Urol*. 2011 Oct 25. IF 8.843
- !2. Carlier RY, Laforet P, Wary C, Mompoin D, Laloui K, **Pellegrini N**, **Annane D**, Carlier PG, **Orlikowski D**. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: Involvement patterns. *Neuromuscul Disord*. 2011 Nov;21(11):791-9. IF 2.6764
 - !3. Caudie C, Quittard Pinon A, Taravel D, Sivadon-Tardy V, **Orlikowski D**, Rozenberg F, Sharshar T, Raphaël JC, Gaillard JL. Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barré syndrome patients. *J Neurol*. 2011 Nov;258(11):1958-64. IF 3.853
 - !4. Chartier Kastler E, Genevois S, Gamé X, **Denys P**, Richard F, Leriche A, Saramon JP, Ruffion A. Treatment of neurogenic male urinary incontinence related to intrinsic sphincter insufficiency with an artificial urinary sphincter: a French retrospective multicentre study. *BJU Int*. 2011 Feb;107(3):426-32. IF 3.190
 - !5. Chartier-Kastler E, **Denys P**. Intermittent catheterization with hydrophilic catheters as a treatment of chronic neurogenic urinary retention. *Neurourol Urodyn*. 2011 Jan;30(1):21-31. IF 2.903
 - !6. de Sèze M, Raibaut P, Gallien P, Even-Schneider A, **Denys P**, Bonniaud V, Gamé X, Amarenco G. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. *Neurourol Urodyn*. 2011 Mar;30(3):306-11. IF 2.903
 - !7. Legrand G, Rouprêt M, Comperat E, Even-Schneider A, **Denys P**, Chartier-Kastler E. Functional outcomes after management of end-stage neurological bladder dysfunction with ileal conduit in a multiple sclerosis population: a monocentric experience. *Urology*. 2011 Oct;78(4):937-41. IF 2.334
 - !8. Lindberg PG, **Bensmail D**, Bussel B, Maier MA, Feydy A. Wallerian degeneration in lateral cervical spinal cord detected with diffusion tensor imaging in four chronic stroke patients. *J Neuroimaging*. 2011 Jan;21(1):44-8. IF 1.287
 - !9. **Orlikowski D**, Porcher R, Sivadon-Tardy V, Quincampoix JC, Raphaël JC, **Durand MC**, Sharshar T, Roussi J, Caudie C, **Annane D**, Rozenberg F, Leruez-Ville M, Gaillard JL, Gault E. Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. *Clin Infect Dis*. 2011 Apr;52(7):837-44. IF 8.186
 - !0. Pradels A, **Pradon D**, Vuillerme N. Effects of experimentally induced pain of the plantar soles on centre of foot pressure displacements during unperturbed upright stance. *Clin Biomech (Bristol, Avon)*. 2011;26(4):424-8. IF 2.036

1. **Quera-Salva MA**, Hartley S, Claustrat B, Brugières L. Circadian rhythm disturbances associated with psychiatric symptoms in a patient with a pineal region tumor. Am J Psychiatry. 2011 Jan;168(1):99-100. IF 12.759
2. Ronco E, **Denys P**, Bernède-Bauduin C, Laffont I, Martel P, Salomon J, Bussel B, **Guillemot D**, Gaillard JL. Diagnostic criteria of urinary tract infection in male patients with spinal cord injury. Neurorehabil Neural Repair. 2011 May;25(4):351-8. IF 3.772
3. Abbara C, **Estournet B**, Lacomblez L, Lelièvre B, Ouslimani A, Lehmann B, Viollet L, Barois A, Diquet B. Riluzole pharmacokinetics in young patients with spinal muscular atrophy. British journal of clinical pharmacology. 2011. IF3.063
4. Blumen M, **Quera Salva MA**, **Vaugier I**, Leroux K, d'Ortho MP, **Barbot E**, Chabolle F, **Lofaso F**. Is snoring intensity responsible for the sleep partner's poor quality of sleep?. Sleep Breath 2011 Jul 10. IF 1.684